Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-MM3: Linvoseltamab vs EPd in Relapsed/Refractory Multiple Myeloma
jRCT2061240057Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab in multiple myeloma (MM) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Progression-free survival in CD38-exposed participants. Started Nov 2024; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061240057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240057.